About | HeinOnline Law Journal Library | HeinOnline Law Journal Library | HeinOnline



56 Calif. L. Rev. 149 (1968)
Some Observations About the Strict Liability of the Maker of Prescription Drugs: The Aftermath of MER/29

handle is hein.journals/calr56 and id is 151 raw text is: Some Observations About the Strict
Liability of the Maker of Prescription
Drugs: The Aftermath of MER/29
Page Keeton*
R EFERENCE HAS OFTEN BEEN MADE to the current scientific and techno-
logical revolution which involves a proliferation of chemicals, espe-
cially drugs and cosmetics.' We are justified in referring to this age as one
both of chemotherapy-the treatment of disease with chemical agents-
and of chemocosmetology-the improvement of appearance through treat-
ment of the skin and hair.' Although most people would admit that this
proliferation of new drugs and cosmetics has on the whole benefited hu-
manity, these benefits to the many are coming at high cost to the few.
Miscarriages can and do often occur in the manufacturing, distributing,
and using processes, with more and more persons being injured as a result.
This increase in harm is accompanied, however, by an enhanced concern
for the injured, provoking a reexamination of those principles, both con-
tractual and tortious, which govern the shifting of losses from those in-
jured to those directing the manufacturing, distributing, and using pro-
cesses.
One consequence of these changes has been a vast increase in litiga-
tion; a single product can often result in claims involving millions of dol-
lars. A recent example is MER/29, which was made and sold as an anti-
cholesterol drug. While it was hoped that MER/29 would have a
significant effect on the rate of heart disease, it caused serious side effects
including cataracts in the eyes of some users and was ultimately with-
drawn from the market. Over a thousand personal injury suits were filed
in its aftermath.4
The observations in this Article flow directly from the appellate opin-
ions in some of those MER/29 cases.5 The variety of judicial results
* Dean, School of Law, University of Texas, Austin.
1 National Observer, May 3, 1965; Address by Edward D. Downing, Peculiar Problems
in Pharmaceutical Cases, at Legal Institute, University of Arkansas, Oct. 1965.
2 Keeton, Products Liability-Some Observations About Allocation of Risks, 64 MIucr.
L. REv. 1329 (1966).
8 See Rheingold, The MER/29 Story-An Instance of Successful Mass Disaster Litiga-
tion, 56 CA.. L. RaV. 116 (1968).
4 Id. at 118.
6See Roginsky v. Richardson-Merrell, Inc., 378 F.2d 832 (2d Cir. 1967); Blum v.
Richardson-Merrell, Inc., 268 F. Supp. 906 (D. Md. 1965); Bennett v. Richardson-Merrell,
Inc., 231 F. Supp. 150 (E.D. Ill. 1964); Toole v. Richardson-Merrell, Inc., 251 A.C.A. 785,
60 Cal. Rptr. 398 (1967); McLeod v. W.S. Merrell Co., 174 So. 2d 736 (Fla. 1965); Lewis